AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37531083 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3405105 monotherapy (QD vs TIW dosing)
Number of subjects: 54
Study 37531083 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3405105 monotherapy (≥15 mg QD)
Number of subjects: 54
Study 37531093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-ritonavir
Number of subjects: 85
Study 37531100 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intervention (LTI) - 4 years, 412 adolescents
Number of subjects: 1326
Study 37531100 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intervention (STI) - 2 years, 504 adolescents
Number of subjects: 1326
Study 37531100 — intervention group
Group type: COMPARATOR
Intervention: Control - standard curriculum, 441 adolescents
Number of subjects: 1326
Study 37531115 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.9% THC cannabis
Number of subjects: 184
Study 37531115 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.4% THC cannabis
Number of subjects: 184
Study 37531115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.02% THC)
Number of subjects: 184
Study 37531115 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving simulator performance
Number of subjects: 184
Study 37531115 — intervention group
Group type: EXPERIMENTAL
Intervention: FST components
Number of subjects: 184
Study 37531115 — intervention group
Group type: COMPARATOR
Intervention: FST performance
Number of subjects: 184
Study 37531115 — intervention group
Group type: EXPERIMENTAL
Intervention: Officer estimation
Number of subjects: 184
Study 37531130 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe (rosuvastatin, 10 mg with ezetimibe, 10 mg)
Number of subjects: 3780
Study 37531633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting full model (GBf)
Number of subjects: 4075
Study 37531633 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model (LR)
Number of subjects: 4075
Study 37531633 — intervention group
Group type: COMPARATOR
Intervention: Single undetectable hs-cTnT-based strategy (u-cTn)
Number of subjects: 4075
Study 37531633 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models and LR
Number of subjects: 4075
Study 37531657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 4 of vaccine at previously received antigen levels (100 or 200 μg)
Number of subjects: 300
Study 37531657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 37531701 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine ICU Recovery Clinic assessments
Number of subjects: 17
Study 37531986 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine
Number of subjects: 180
Study 37531986 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of normal saline
Number of subjects: 180
Study 37531986 — intervention group
Group type: COMPARATOR
Intervention: No administration
Number of subjects: 180
Study 37532066 — intervention group
Group type: COMPARATOR
Intervention: Diet-induced weight loss and standard care
Number of subjects: 80
Study 37532066 — intervention group
Group type: EXPERIMENTAL
Intervention: Three exercise sessions per week in adjunct to diet-induced weight loss
Number of subjects: 80
Study 37532066 — intervention group
Group type: EXPERIMENTAL
Intervention: Six exercise sessions per week in adjunct to diet-induced weight loss
Number of subjects: 80
Study 37532157 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral treprostinil
Number of subjects: 29
Study 37532250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intracanalicular insert
Number of subjects: 20
Study 37532250 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone eyedrops (tapering schedule)
Number of subjects: 20
Study 37532416 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin-AVD
Number of subjects: 41
Study 37532482 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency treatment
Number of subjects: 200
Study 37532482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency treatment
Number of subjects: 200
Study 37532482 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 200
Study 37532611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent live attenuated dengue vaccine
Number of subjects: 60
Study 37532611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37532622 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN120 (100 mg/day)
Number of subjects: 82
Study 37532622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 37532921 — intervention group
Group type: COMPARATOR
Intervention: Moderate physical activity
Number of subjects: 240
Study 37532921 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose high fat dietary patterns
Number of subjects: 240
Study 37532921 — intervention group
Group type: COMPARATOR
Intervention: Monomethyl phthalate (MMP)
Number of subjects: 240
Study 37532921 — intervention group
Group type: COMPARATOR
Intervention: Monobutyl phthalate (MnBP)
Number of subjects: 240
Study 37532921 — intervention group
Group type: COMPARATOR
Intervention: Consumption of vegetables, fruits, and tonic
Number of subjects: 240
Study 37532921 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fried food, western fast food, carbonated drinks, and juice
Number of subjects: 240
Study 37532929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological targeting of netrin-1
Number of subjects: 0
Study 37532933 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation probiotics, specific details on dosage and duration not available
Number of subjects: 0
Study 37532979 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tVNS stimulation (stimulation at cymba conchae of left ear)
Number of subjects: 40
Study 37532979 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS stimulation (at earlobe)
Number of subjects: 40
Study 37532979 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tVNS stimulation
Number of subjects: 40
Study 37532979 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS stimulation
Number of subjects: 40
Study 37532985 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of antipsychotics
Number of subjects: 0
Study 37533033 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g of LC-L-tartrate and 3 g of leucine per day)
Number of subjects: 27
Study 37533033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 g of leucine per day)
Number of subjects: 27
Study 37533058 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS treatment (active)
Number of subjects: 80
Study 37533058 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS treatment (placebo)
Number of subjects: 80
Study 37533073 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered multifactorial fall injury prevention intervention
Number of subjects: 5451
Study 37533073 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 5451
Study 37533096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) for 12 weeks
Number of subjects: 72
Study 37533096 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 72
Study 37533228 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term temozolomide (TMZ) treatment
Number of subjects: 6
Study 37533228 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment
Number of subjects: 6
Study 37533228 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 6
Study 37533380 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben 5 mg
Number of subjects: 242
Study 37533380 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben 25 mg
Number of subjects: 242
Study 37533380 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben 50 mg
Number of subjects: 242
Study 37533380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 37533380 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben (all doses combined)
Number of subjects: 242
Study 37533416 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus evening mobilisation
Number of subjects: 58
Study 37533416 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 37533418 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 2939
Study 37533418 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of antibody response
Number of subjects: 2939
Study 37533418 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence
Number of subjects: 2939
Study 37533419 — intervention group
Group type: EXPERIMENTAL
Intervention: MV(D614) booster
Number of subjects: 3077
Study 37533419 — intervention group
Group type: EXPERIMENTAL
Intervention: MV(B.1.351) booster
Number of subjects: 3077
Study 37533419 — intervention group
Group type: EXPERIMENTAL
Intervention: BiV booster
Number of subjects: 3077
Study 37533419 — intervention group
Group type: EXPERIMENTAL
Intervention: All booster formulations
Number of subjects: 3077
Study 37533419 — intervention group
Group type: EXPERIMENTAL
Intervention: All booster groups
Number of subjects: 3077
Study 37533476 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intracranial Calcification Score (ICCS)
Number of subjects: 531
Study 37533476 — intervention group
Group type: COMPARATOR
Intervention: Low Intracranial Calcification Score (ICCS)
Number of subjects: 531
Study 37533523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite toothpaste (test)
Number of subjects: 189
Study 37533523 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste (1450 ppm fluoride; positive control)
Number of subjects: 189
Study 37533588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine treatment (serial intravenous infusions)
Number of subjects: 26
Study 37533657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy (HILT) + stretching exercise
Number of subjects: 40
Study 37533657 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT) + stretching exercise
Number of subjects: 40
Study 37533665 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-intensity interval training session
Number of subjects: 0
Study 37533773 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (add-on treatment)
Number of subjects: 0
Study 37533867 — intervention group
Group type: EXPERIMENTAL
Intervention: rBCG-N-hRSV vaccine
Number of subjects: 0
Study 37533941 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37533995 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation group (rTMS)
Number of subjects: 60
Study 37533995 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60
Study 37534453 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 38
Study 37534453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 37534515 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex Sequencing (DS)
Number of subjects: 62
Study 37534515 — intervention group
Group type: COMPARATOR
Intervention: Multiparametric Flow Cytometry (MFC)
Number of subjects: 62
Study 37534514 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor clone of del(17p) at relapse
Number of subjects: 995
Study 37534514 — intervention group
Group type: COMPARATOR
Intervention: Patients without del(17p) during follow-up
Number of subjects: 995
Study 37534514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who acquired del(17p) during their disease course
Number of subjects: 995
Study 37534543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (a SYK inhibitor)
Number of subjects: 0
Study 37534543 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37534543 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37534686 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 0
Study 37534686 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive management of adverse events
Number of subjects: 0
Study 37534695 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in PWH
Number of subjects: 512
Study 37534695 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccination in HIV-negative individuals
Number of subjects: 512
Study 37534695 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in PWH with past COVID-19 infection
Number of subjects: 512
Study 37534695 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccination in HIV-negative individuals with past COVID-19 infection
Number of subjects: 512
Study 37534922 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body ergometer rowing exercise
Number of subjects: 0
Study 37534999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanovesicle technology
Number of subjects: 0
Study 37534999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy using nanovesicles
Number of subjects: 0
Study 37534996 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus nab-paclitaxel in combination with indoximod
Number of subjects: 16
Study 37535240 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (AVAL) at a dosage of 20 mg/kg
Number of subjects: 91
Study 37535240 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (AVAL) at a dosage of 40 mg/kg
Number of subjects: 91
Study 37535316 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen during exercise training
Number of subjects: 28
Study 37535316 — intervention group
Group type: COMPARATOR
Intervention: Medical air during exercise training
Number of subjects: 28
Study 37535330 — intervention group
Group type: EXPERIMENTAL
Intervention: Online circuit training (3 sessions per week for 12 weeks)
Number of subjects: 60
Study 37535330 — intervention group
Group type: COMPARATOR
Intervention: Control group (website to help reach physical activity guidelines)
Number of subjects: 60
Study 37535330 — intervention group
Group type: EXPERIMENTAL
Intervention: Online circuit training
Number of subjects: 60
Study 37535330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 37535352 — intervention group
Group type: EXPERIMENTAL
Intervention: PediAppRREST app
Number of subjects: 300
Study 37535352 — intervention group
Group type: COMPARATOR
Intervention: PALS control group (paper-based cognitive aid)
Number of subjects: 300
Study 37535352 — intervention group
Group type: COMPARATOR
Intervention: Null control group (no cognitive aids)
Number of subjects: 300
Study 37535357 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioral therapy (tele-CBT) consisting of 6 weekly 1-hour sessions and a booster session 1 month later.
Number of subjects: 306
Study 37535357 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative bariatric care (control group).
Number of subjects: 306
Study 37535377 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (200 mg camrelizumab, nab-paclitaxel 130 mg/m2, cisplatin 75 mg/m2 or carboplatin AUC 5 or nedaplatin 100 mg/m2)
Number of subjects: 94
Study 37535377 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 94
Study 37535377 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 94
Study 37535382 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept, 8 mg (70 μL)
Number of subjects: 106
Study 37535382 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept, 2 mg (50 μL)
Number of subjects: 106
Study 37535388 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab every 2 weeks until progression, unacceptable toxic effects, or patient refusal
Number of subjects: 122
Study 37535388 — intervention group
Group type: COMPARATOR
Intervention: Standard second-line chemotherapy
Number of subjects: 122
Study 37535388 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 122
Study 37535416 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning Clinical Decision Support (ML-CDS) tool
Number of subjects: 339
Study 37535416 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-CDS intervention
Number of subjects: 339
Study 37535416 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-CDS tool
Number of subjects: 339
Study 37535419 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of melatonin
Number of subjects: 60
Study 37535419 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of melatonin
Number of subjects: 60
Study 37535419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37535419 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized trial approach
Number of subjects: 60
Study 37535419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment measures
Number of subjects: 60
Study 37535419 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence measures
Number of subjects: 60
Study 37535521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ABC-I)
Number of subjects: 149
Study 37535521 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 149
Study 37535555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT) ROC-T
Number of subjects: 92
Study 37535555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) ROC-T
Number of subjects: 92
Study 37535555 — intervention group
Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 92
Study 37535575 — intervention group
Group type: EXPERIMENTAL
Intervention: DAIVE (decision analysis for intervention value efficiency)
Number of subjects: 0
Study 37535575 — intervention group
Group type: EXPERIMENTAL
Intervention: DAIVE
Number of subjects: 0
Study 37535580 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of grief symptoms at 2 months postloss
Number of subjects: 1224
Study 37535580 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD, PTSD, and depression
Number of subjects: 1224
Study 37535580 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age and losing a spouse
Number of subjects: 1224
Study 37535580 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-person differences
Number of subjects: 1224
Study 37535618 — intervention group
Group type: COMPARATOR
Intervention: Propofol (P group)
Number of subjects: 304
Study 37535618 — intervention group
Group type: COMPARATOR
Intervention: Remimazolam tosylate (RT group)
Number of subjects: 304
Study 37535618 — intervention group
Group type: COMPARATOR
Intervention: Remimazolam tosylate plus propofol (R+P group)
Number of subjects: 304
Study 37535618 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of remimazolam tosylate and propofol (R+P group)
Number of subjects: 304
Study 37535624 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise program (group I, 20 participants)
Number of subjects: 40
Study 37535624 — intervention group
Group type: COMPARATOR
Intervention: Posture exercise program (group II, 20 participants)
Number of subjects: 40
Study 37535624 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise program (group I)
Number of subjects: 40
Study 37535693 — intervention group
Group type: EXPERIMENTAL
Intervention: PPKAY (Brief Negotiational Interview)
Number of subjects: 75
Study 37535693 — intervention group
Group type: EXPERIMENTAL
Intervention: PPKAY with standard text booster
Number of subjects: 75
Study 37535693 — intervention group
Group type: EXPERIMENTAL
Intervention: PPKAY with personalized text booster
Number of subjects: 75
Study 37535693 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 75
Study 37535695 — intervention group
Group type: EXPERIMENTAL
Intervention: O. volvulus positive epilepsy/nodding syndrome patients
Number of subjects: 0
Study 37535695 — intervention group
Group type: EXPERIMENTAL
Intervention: O. volvulus positive nodding syndrome patients
Number of subjects: 0
Study 37535695 — intervention group
Group type: COMPARATOR
Intervention: O. volvulus negative individuals
Number of subjects: 0
Study 37535775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone injection
Number of subjects: 45
Study 37535775 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 45
Study 37535775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency application
Number of subjects: 45
Study 37535775 — intervention group
Group type: COMPARATOR
Intervention: All interventions (Ozone, Steroid, Pulsed Radiofrequency)
Number of subjects: 45
Study 37535876 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX + PAN
Number of subjects: 183
Study 37535876 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + LV + PAN
Number of subjects: 183
Study 37535937 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 37535953 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no HBV treatment)
Number of subjects: 3
Study 37535953 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (single HBV treatment)
Number of subjects: 3
Study 37535953 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (dual HBV treatment)
Number of subjects: 3
Study 37535953 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 3
Study 37536444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator response (BDR) defined by four different definitions, assessed using albuterol.
Number of subjects: 931
Study 37536633 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-scope helix tack suture system (TTSS)
Number of subjects: 40
Study 37536633 — intervention group
Group type: COMPARATOR
Intervention: Over-the-scope suturing system (OTSS)
Number of subjects: 40
Study 37536635 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted novice group (AN)
Number of subjects: 685
Study 37536671 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD (S-ICD)
Number of subjects: 628
Study 37536680 — intervention group
Group type: EXPERIMENTAL
Intervention: Choose to Move (CTM) virtual intervention
Number of subjects: 153
Study 37536752 — intervention group
Group type: COMPARATOR
Intervention: 2019 (Control)
Number of subjects: 430